A population pharmacokinetic model of gabapentin developed in nonparametric adaptive grid and nonlinear mixed effects modeling

Therapeutic Drug Monitoring

Volumn 31, Issue 1, 2009, Pages 86-94

  Carlsson, Kristin C ^a,b,e   Van De Schootbrugge, Margunn ^a   Eriksen, Heidi Oien ^a   Moberg, Enrica Ratti ^c   Karlsson, Mats O ^b   Hoem, Nils Ove ^a,d,f  

^a UNIVERSITY OF OSLO   (Norway)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY OF OSLO   (Norway)

^d MDS Pharma Services   (Germany)

^e NOVO NORDISK A S   (Denmark)

^f former employee of Aker BioMarine Antarctic AS   (Norway)

Author keywords

Gabapentin; Neuropathic pain; NONMEM; NPAG; Therapeutic drug monitoring

Indexed keywords

CREATININE; GABAPENTIN;

ADULT; ARTICLE; BAYES THEOREM; BODY WEIGHT; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; FEMALE; HUMAN; INDIVIDUAL BASED POPULATION MODEL; MALE; NEUROPATHIC PAIN; PRIORITY JOURNAL; STEADY STATE;

ADULT; AGED; ALGORITHMS; AMINES; AREA UNDER CURVE; BAYES THEOREM; BIOLOGICAL AVAILABILITY; CYCLOHEXANECARBOXYLIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; NONLINEAR DYNAMICS; PAIN; PERIPHERAL NERVOUS SYSTEM DISEASES; POPULATION; SOFTWARE; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 60449087148     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318194767d     Document Type: Article

References (25)

1. Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998;280: 1837-1842.
2. Serpell MG. Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. Pain. 2002;99:557-566.
3. Vollmer KO, von Hodenberg A, Kolle EU, Pharmacokinetics and metabolism of gabapentin in rat, dog and man. Arzneimittelforschung. 1986;36:830-839.
4. Goa KL, Sorkin EM. Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy. Drugs. 1993;46:409-427.
5. Vollmer KO, Anhut H, Thomann P, et al. Pharmacokinetic model and absolute bioavailability of the new anticonvulsant gabapentin. In: Bental E, et al, eds. Advances in Epileptology. New York: Raven Press, Ltd., 1989; 17:209-211.
6. McLean MJ. Clinical pharmacokinetics of gabapentin. Neurology. 1994; 44:S17-S22.
7. Stewart BH, Kugler AR, Thompson PR, et al. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res. 1993;10:276-281.
8. Luer MS, Hamani C, Dujovny M, et al. Saturable transport of gabapentin at the blood-brain barrier. Neurol Res. 1999;21:559-562.
9. Berry DJ, Beran RG, Plunkeft MJ, et al. The absorption of gabapentin following high dose escalation. Seizure. 2003;12:28-36.
10. Wilson EA, Sills GJ, Forrest G, et al. High dose gabapentin in refractory partial epilepsy: clinical observations in 50 patients. Epilepsy Res. 1998; 29:161-166.
11. Gidal BE, DeCerce J, Bockbrader HN, et al. Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy. Epilepsy Res. 1998;31:91-99.
12. Lockwood PA, Cook JA, Ewy WE, et al. The use of clinical trial simulation to support dose selection: application to development of a new treatment for chronic neuropathic pain. Pharm Res. 2003;20:1752-1759.
13. Gidal BE, Radulovic LL, Kruger S, et al. Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Res. 2000;40:123-127.
14. Carlsson KC, Reubsaet JLE. Sample preparation and determination of gabapentin in venous and capillary blood using liquid chromatographytandem mass spectrometry. J Pharm Biomed Anal. 2004;34:415-423.
15. Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005; 79:241-257.
16. Bayard DS, Jelliffe RW. A Bayesian approach to tracking patients having changing pharmacokinetic parameters. J Pharmacokinet Pharmacodyn. 2004;31:75-107.
17. Bonate PL. Coverage and precision of confidence intervals for area under the curve using parametric and non-parametric methods in a toxicokinetic experimental design. Pharm Res. 1998;15:405-410.
18. Macdonald I, Staatz CE, Jelliffe RW, et al. Evaluation and comparison of simple multiple model, richer data multiple model, and sequential interacting multiple model (IMM) Bayesian analyses of gentamicin and vancomycin data collected from patients undergoing cardiothoracic surgery. Ther Drug Monit. 2008;30:67-74.
19. Graves NM. Pharmacokinetics of gabapentin in patients treated with phenytoin. Pharmacotherapy. 1989;9:196.
20. Savic RM, Kjellsson MC, Karlsson MO. Evaluation of the nonparametric estimation method in NONMEM VI beta. PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe. 2006; Abstr 937. ISSN: 1871-6032. Available from: http://www.page-meeting.org/?abstract=937.
21. Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49:1239-1276.
22. Bennett MI, Simpson KH. Gabapentin in the treatment of neuropathic pain. Palliat Med. 2004;18:5-11.
23. Parsons B, Tive L, Huang S. Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. Am J Geriatr Pharmacother. 2004;2:157-162.
24. Beydoun A, Fakhoury T, Nasreddine W, et al. Conversion to high dose gabapentin monotherapy in patients with medically refractory partial epilepsy. Epilepsia. 1998;39:188-193.
25. Baulac M, Cavalcanti D, Semah F, et al. Gabapentin add-on therapy with adaptable dosages in 610 patients with partial epilepsy: an open, observational study. The French Gabapentin Collaborative Group. Seizure. 1998;7:55-62.